Trial reportMalaria journal2009
Safety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali.
Trial report in Malaria journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00697164 (Randomized Trial of Erythropoietin to Prevent Death From Cerebral Impairment During Severe Malaria), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial of Erythropoietin to Prevent Death From Cerebral Impairment During Severe Malaria
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Hormones in malaria infection: influence on disease severity, host physiology, and therapeutic opportunities.Bioscience reports · 2024Review
- Modelling heme-mediated brain injury associated with cerebral malaria in human brain cortical organoids.Scientific reports · 2019Article
- Adjunctive therapy for severe malaria: a review and critical appraisal.Malaria journal · 2018Review
- A Neuroprotective Effect of the Glutamate Receptor Antagonist MK801 on Long-Term Cognitive and Behavioral Outcomes Secondary to Experimental Cerebral Malaria.Molecular neurobiology · 2017Article
- Do we know enough to find an adjunctive therapy for cerebral malaria in African children?F1000Research · 2017Review
- Article
- High plasma erythropoietin levels are associated with prolonged coma duration and increased mortality in children with cerebral malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
- Systemic and Cerebral Vascular Endothelial Growth Factor Levels Increase in Murine Cerebral Malaria along with Increased Calpain and Caspase Activity and Can be Reduced by Erythropoietin Treatment.Frontiers in immunology · 2014Article
- Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice.Frontiers in immunology · 2014Article
- Erythropoietin treatment alleviates ultrastructural myelin changes induced by murine cerebral malaria.Malaria journal · 2012Article
- Cytoadherence and severe malaria.The Malaysian journal of medical sciences : MJMS · 2012Article
- Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2011Review
- The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria.Malaria journal · 2011Review
- Novel avenues of drug discovery and biomarkers for diabetes mellitus.Journal of clinical pharmacology · 2011Review
- Plasmodium falciparum metacaspase PfMCA-1 triggers a z-VAD-fmk inhibitable protease to promote cell death.PloS one · 2011Article
- The 'hidden' burden of malaria: cognitive impairment following infection.Malaria journal · 2010Review
- Apoptosis induced by parasitic diseases.Parasites & vectors · 2010Article
- Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome.Pediatric research · 2010Review
- Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria.Expert review of anti-infective therapy · 2010Review
- Cerebral malaria: a vasculopathy.The American journal of pathology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebral malaria carries an unacceptable case fatality rate in children despite timely and adequate chemotherapy. To improve the survival rate, adjunctive therapies previously tested mainly focused on the modulation of the inflammatory response, without definitive effect in humans. In this context, a new adjunctive strategy using a neuroprotective drug: erythropoietin (epoietin-beta, Epo) was proposed.
methodsAn open-labelled study including cerebral malaria children (Blantyre coma score below 3) was conducted in Mali. The objective was to assess the short-term safety (seven days) of erythropoietin at high doses (1,500 U/kg/day during three days) combined to quinine.
results35 patients with unrousable coma were included in the study. None of expected side effects of erythropoietin were observed during the seven days follow-up. No significant increase in the case fatality rate (7/35 patients) was observed compared to other studies with mortality rates ranging from 16 to 22% in similar endemic areas.
conclusionThese data provide the first evidence of the short-term safety of erythropoietin at high doses combined to quinine. A multicentre study is needed to assess the potential of Epo as an adjunctive therapy to increase the survival during cerebral malaria. CLINICAL REGISTRATION NUMBER: ClinicalTrials.gov ID: NCT00697164.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.